Targets › SGCG
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Jan 2031.
Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix. (UniProt, Q13326)
Open in Phaseline: the race on SGCG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Atamyo Therapeutics | ATA-200 SGCG gene replacement therapy | SGCG | Phase 1 | LGMD2C | Jan 2031 |
LGMD2C (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.